EUCTR2005-004834-42-HUActive, not recruitingNot Applicable
A Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Safety Study ofPulmonary Function in Patients with Reduced Lung Function Treated with BOTOX®(Botulinum Toxin Type A) Purified Neurotoxin Complex for Focal Upper LimbSpasticity Due to Upper Motor Neuron Syndrome
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Allergan
- Enrollment
- 150
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Male or female, 18 years of age or older
- •2. Written informed consent
- •3. Written Authorization for Use and Release of Health and Research Study
- •Information has been obtained.
- •4. Medically stable subjects with stable compromised baseline respiratory
- •status who have spastic muscles in at least the upper limb that manifests as
- •common spasticity induced patterns of the upper motor neuron syndrome
- •5. History of upper motor neuron syndrome that results in upper limb spasticity
- •of one or both upper limbs (spasticity in lower limb is allowed but will not
- •be treated with study medication)
- •6. In the opinion of the investigator, the subject has sufficient spasticity in an
- •affected upper limb, to be designated as the study limb, to warrant a dose of
- •360 U of BOTOX®
- •7. Stable pulmonary condition defined as no history of acute pulmonary
- •complications within the past 4 months (e.g. hospitalization for exacerbation
- •of chronic obstructive pulmonary disease, pneumonia, obvious reactive
- •airway disease diagnosed by signs and symptoms, abnormal chest x-ray
- •readings, etc.)
- •8. The largest FEV1 must be 40% to 80% of the predicted value at Visit 1 and
- •Visit 2, and the largest FEV1 value at Visit 2 must not vary more than 20% of
- •the largest value at Visit 1
- •9. The largest FVC value at Visit 2 must not vary more than 20% of the largest
- •FVC value at Visit 1
- •10. Ability to perform acceptable and reproducible FEV1 and FVC according to
- •1995 ATS spirometry guidelines
- •11. Ability to follow study instructions and likely to complete all required visits
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •1. Stroke within 6 months of Visit 2
- •2. Known allergy or sensitivity to the study medication or its components
- •3. Previous therapy with BOTOX or any other botulinum toxin for any
- •4. Females who are pregnant, nursing, or planning a pregnancy during the
- •study, or females of childbearing potential, not using a reliable means of
- •contraception
- •5. Subjects with multiple sclerosis or primary lateral sclerosis where
- •progression of the disease may confound study results
- •6. Any medical condition that may put the subject at increased risk with
- •exposure to BOTOX® including diagnosed myasthenia gravis, Eaton-
- •Lambert Syndrome, amyotrophic lateral sclerosis, or any other disorder that
- •might interfere with neuromuscular transmission
- •7. More than one overnight hospitalization or 2 emergency room visits for
- •respiratory related event(s) in the last 12 months
- •8. Infection or dermatological condition at anticipated injection sites
- •9. Current treatment with an intrathecal baclofen pump
- •10. Changes in corticosteroid medication dose/regimen in the last 2 months
- •11. Current enrollment in an investigational drug or device study or participation
- •in such a study within 30 days of entry into this study
- •12. Subject has a condition or is in a situation which in investigator's opinion
- •may put the subject at significant risk, may confound the study results, or
- •may interfere significantly with the subject's participation in the study
Investigators
Similar Trials
Active, not recruiting
Not Applicable
A Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Safety Study ofPulmonary Function in Patients with Reduced Lung Function Treated with BOTOX®(Botulinum Toxin Type A) Purified Neurotoxin Complex for Focal Upper LimbSpasticity Due to Upper Motor Neuron SyndromeFocal upper limb spasticity due to upper motor neuron syndromeincluding poststroke spasticity. (for the objective of this study patients must also have stable compromised baseline respiratory status)MedDRA version: 8.1Level: PTClassification code 10028335EUCTR2005-004834-42-CZAllergan150
Active, not recruiting
Not Applicable
A Multi-Centre, Double-Blind, Placebo-Controlled, Parallel-Group Induction-Design Study to assess the Clinical Effect of Droxidopa in Subjects with Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic Neurogenic Orthostatic HypotensioEUCTR2008-002855-26-ATChelsea Therapeutics Inc176
Active, not recruiting
Not Applicable
A Multi-Centre, Double-Blind, Placebo-Controlled, Ascending-Dose, Clinical Trial of Intra-venous Microplasmin Administration in Patients with Acute Ischemic Stroke - MITI-IVEUCTR2005-001074-27-BEThromboGenics Ltd.40
Active, not recruiting
Not Applicable
A Multi-Centre, Double-Blind, Placebo-Controlled, Parallel-Group Induction-Design Study to assess the Clinical Effect of Droxidopa in Subjects with Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic Neurogenic Orthostatic HypotensioSymptomatic neurogenic orthostatic hypotension (NOH) in patients with Primary Autonomic Failure (Pharmacodynamic, MSA and PAF), DBH deficiency and Non-Diabetic Neuropathy.EUCTR2008-002855-26-DEChelsea Therapeutics Inc176
Active, not recruiting
Not Applicable
A Multi-Centre, Double-Blind, Placebo-Controlled, Ascending-Dose, Clinical Trial of Intra-venous Microplasmin Administration in Patients with Acute Ischemic Stroke - MITI-IVEUCTR2005-001074-27-ATThromboGenics Ltd.40